With the popular social media app once again at risk of going dark, there are best practices pharma brands can use on other ...

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Biohaven Pharmaceutical Holding Co (NYSE:BHVN) Ltd on Tuesday,... H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on ...

Deutsche Bank says Biohaven’s (BHVN) competitor Immunovant (IMVT) reported topline data for FcRn antibody batoclimab in myasthenia gravis and ...

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Biohaven Pharmaceutical Holding Co (NYSE:BHVN) Ltd on Tuesday,... Wedbush analyst Laura Chico maintained a Buy rating on Biohaven ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff after shelving two cell therapy programs.

Piper Sandler analyst Allison Bratzel maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) today and set a price target of ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. The registrational study assessed BHV-7000, a drug designed to selectively activate Kv7.2/Kv7.3 ...

Shares of Biohaven stock opened at $37.24 on Thursday. The business’s 50 day simple moving average is $38.20 and its two-hundred day simple moving average is $42.75. The stock has a market ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

Biohaven has a 1 year low of $26.80 and a 1 year high of $60.46. The stock’s 50-day simple moving average is $37.06 and its 200-day simple moving average is $42.08.

NASHVILLE, Tenn., Feb. 25, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its annual 2024 financial ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $63 from $69 and keeps an Overweight rating on the shares. Biohaven reported Q4 earnings on March 3 and provided “mixed ...